References
- Yang L, Ying X, Liu S, et al. Gastric cancer: epidemiology, risk factors and prevention strategies. Chin J Cancer Res. 2020;32(6):695–704.
- Eto K, Hiki N, Kumagai K, et al. Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer. 2018;21(4):703–709.
- Melamed A, Hinchcliff EM, Clemmer JT, et al. Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. Gynecol Oncol. 2016;143(2):236–240.
- Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the east. Dig Surg. 2013;30(2):119–129.
- Tang X, He Q, Qu H, et al. Post-therapy pathologic tumor volume predicts survival in gastric cancer patients who underwent neoadjuvant chemotherapy and gastrectomy. BMC Cancer. 2019;19(1):1–8.
- Kondo M, Nishino S, Yamashita D, et al. Complete response of locally advanced gastric cancer with pancreatic invasion and gastric outlet obstruction after neoadjuvant chemotherapy with S-1 and oxaliplatin. Case Rep Oncol. 2020;13(2):716–720.
- Feng D, Leong M, Li T, et al. Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy. World J Surg Oncol. 2015;13(1):11–19.
- Cai M, Zeng XY, Xiong Z, et al. Early postoperative complications and risk factors in laparoscopic D2 radical gastrectomy for gastric cancer. Zhonghua Wei Chang Wai ke za Zhi = Chinese J Gastrointest Surg. 2019;22(8):742–747.
- Wilke H, Preusser P, Fink U, et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol. 1989;7(9):1318–1326.
- Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
- Ychou M, Boige V, Pignon J-P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–1721.
- Fujitani K, Ajani JA, Crane CH, et al. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007;14(7):2010–2017.
- Valenti V, Hernandez‐Lizoaín JL, Beorlegui MC, et al. Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy. J Surg Oncol. 2011;104(2):124–129.
- Yu J, Hu J, Huang C, Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group, et al. The impact of age and comorbidity on postoperative complications in patients with advanced gastric cancer after laparoscopic D2 gastrectomy: results from the chinese laparoscropic gastrointestinal surgery study (CLASS) group. Eur J Surg Oncol. 2013;39(10):1144–1149.
- Kim T-H, Suh Y-S, Huh Y-J, et al. The comprehensive complication index (CCI) is a more sensitive complication index than the conventional clavien–dindo classification in radical gastric cancer surgery. Gastric Cancer. 2018;21(1):171–181.